All In Biotech

Free tool

FAERS Monitor: Vivjoa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215888 or its brand name (Vivjoa, Oteseconazole). Reports on generic versions are filed under their own applications.

Reports

43

Serious

3

7% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective8
  • fungal infection5
  • dysuria4
  • inappropriate schedule of product administration4
  • off label use4
  • vulvovaginal pruritus4
  • dizziness3
  • nausea3
  • candida infection2
  • diarrhoea2
  • erythema2
  • headache2
  • hot flush2
  • insomnia2
  • pain2

Reports by year received

View as table
YearReports
202314
20249
20254
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,116 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vulvovaginal pruritusSignal4386.6152.01,176
fungal infectionSignal573.432.2289
candida infection257.915.062
dysuriaSignal453.220.9156
hot flush213.03.412
inappropriate schedule of product administrationSignal410.94.327
erythema24.81.23
insomnia23.70.92
drug ineffectiveSignal83.01.69
dizziness32.91.02
off label use42.20.92
nausea31.90.60
pain21.60.40
headache21.60.40
diarrhoea21.50.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.